CLNN - Clene rises 7.5% on positive data from phase 2 trial of ALS treatment

2023-03-06 09:25:11 ET

• Clene ( NASDAQ: CLNN ) is trading 7.5% higher premarket after the company said new data from a phase 2 trial showed its therapy, CNM-Au8, preserved ALS patient function and slowed disease progression.
• Patients during the trial were given the therapy for over 48-weeks and were measured by the ALSFRS-R, a clinical assessment measuring activities such as walking, speaking, breathing, feeding, and dressing independently.
• The study participants, which were about 45, were randomized 1:1 to receive 30 mg of CNM-Au8 or placebo daily for 36 weeks, followed by an open-label extension (OLE) period that extended treatment indefinitely.
• The treatment also showed a statistical significant reduction in risk of ALS clinical worsening by 52% over 120 weeks.
• "The open-label data at 48 weeks and through 120 weeks from randomization suggests that CNM-Au8 has the ability to meaningfully improve patient daily functional status over longer periods of time, together with sustained treatment effects on ALS disease progression and survival," said Matthew Kiernan, the trial’s clinical advisors.
• Amyotrophic lateral sclerosis or ALS is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control.
• Press Release

For further details see: